NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

Strain-Dependent Epithelial Defects in Mice Lacking the EGF Receptor

Sibilia, M., & Wagner, E. F. (1995) · Science · doi:10.1126/science.7618085 · Cited by 1,002

Autophosphorylation sites on the epidermal growth factor receptor

Downward, J., Parker, P., & Waterfield, M. D. (1984) · Nature · doi:10.1038/311483a0 · Cited by 704

Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.

Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698

Cell Signaling by Receptor Tyrosine Kinases

Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Cell Signaling by Receptor Tyrosine Kinases

Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027

Androgen Receptor in Prostate Cancer

Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780

Epidermal growth factor receptor: Mechanisms of activation and signalling

Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565

ErbB receptors and signaling pathways in cancer

Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773

Phosphotyrosine interactome of the ErbB‐receptor kinase family

Schulze, W. X., Deng, L., & Mann, M. (2005) · Molecular Systems Biology · doi:10.1038/msb4100012 · Cited by 753

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677

Signal transduction and oncogenesis by ErbB/HER receptors

Marmor, M. D., Skaria, K. B., & Yarden, Y. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.06.002 · Cited by 389

Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas

Montero-Conde, C., Ruiz-Llorente, S., Dominguez, J. M., Knauf, J. A., Viale, A., Sherman, E. J., Ryder, M., Ghossein, R. A., Rosen, N., & Fagin, J. A. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0531 · Cited by 382

Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival

Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients

Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014835108 · Cited by 337

Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy

Qiao, Y., Wan, J., Zhou, L., Ma, W., Yang, Y., Luo, W., Yu, Z., & Wang, H. (2019) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1527 · Cited by 332

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5123 · Cited by 319

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291

Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation

Lichtenberger, B. M., Gerber, P. A., Holcmann, M., Buhren, B. A., Amberg, N., Smolle, V., Schrumpf, H., Boelke, E., Ansari, P., Mackenzie, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005886 · Cited by 241

A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling

HATAKEYAMA, M., KIMURA, S., NAKA, T., KAWASAKI, T., YUMOTO, N., ICHIKAWA, M., KIM, J.-H., SAITO, K., SAEKI, M., SHIROUZU, M., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021824 · Cited by 233

Neuregulin/ErbB Signaling Regulates Cardiac Subtype Specification in Differentiating Human Embryonic Stem Cells

Zhu, W.-Z., Xie, Y., Moyes, K. W., Gold, J. D., Askari, B., & Laflamme, M. A. (2010) · Circulation Research · doi:10.1161/circresaha.110.223917 · Cited by 228

Biology of Interactions: Antiepidermal Growth Factor Receptor Agents

Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214

The ErbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Rowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor

Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3407 · Cited by 151

UBPY-mediated Epidermal Growth Factor Receptor (EGFR) De-ubiquitination Promotes EGFR Degradation

Alwan, H. A. J., & van Leeuwen, J. E. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m604711200 · Cited by 140

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

Chakrabarty, A., Bhola, N. E., Sutton, C., Ghosh, R., Kuba, M. G., Dave, B., Chang, J. C., & Arteaga, C. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2440 · Cited by 130

Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1

Cao, Z., Wu, X., Yen, L., Sweeney, C., & Carraway, K. L. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01245-06 · Cited by 119

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer

Kyula, J. N., Van Schaeybroeck, S., Doherty, J., Fenning, C. S., Longley, D. B., & Johnston, P. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0014 · Cited by 99

Epithelial-mesenchymal transition orchestrates tumor microenvironment: Current perceptions and challenges

Xie, Y., Wang, X., Wang, W., Pu, N., & Liu, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06422-5 · Cited by 80

The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein

Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70

Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects

Goishi, K., Lee, P., Davidson, A. J., Nishi, E., Zon, L. I., & Klagsbrun, M. (2003) · Mechanisms of Development · doi:10.1016/s0925-4773(03)00068-6 · Cited by 70

The Candida albicans toxin candidalysin mediates distinct epithelial inflammatory responses through p38 and EGFR-ERK pathways

Nikou, S.-A., Zhou, C., Griffiths, J. S., Kotowicz, N. K., Coleman, B. M., Green, M. J., Moyes, D. L., Gaffen, S. L., Naglik, J. R., & Parker, P. J. (2022) · Science Signaling · doi:10.1126/scisignal.abj6915 · Cited by 65

Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer

Tomek, K., Wagner, R., Varga, F., Singer, C. F., Karlic, H., & Grunt, T. W. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0467 · Cited by 64

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

Juric, D., Dienstmann, R., Cervantes, A., Hidalgo, M., Messersmith, W., Blumenschein, G. R., Tabernero, J., Roda, D., Calles, A., Jimeno, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2412 · Cited by 59

AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo

Xie, H., Lin, L., Tong, L., Jiang, Y., Zheng, M., Chen, Z., Jiang, X., Zhang, X., Ren, X., Qu, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021487 · Cited by 48

Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR

Basu, D., Richters, A., & Rauh, D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.038 · Cited by 50

Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer

Park, J., Sarode, V. R., Euhus, D., Kittler, R., & Scherer, P. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214400109 · Cited by 44

Degradation of HER2 by Cbl-Based Chimeric Ubiquitin Ligases

Li, X., Shen, L., Zhang, J., Su, J., Shen, L., Liu, X., Han, H., Han, W., & Yao, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3731 · Cited by 37

miR-155 and miR-146a collectively regulate meningitic Escherichia coli infection-mediated neuroinflammatory responses

Yang, B., Yang, R., Xu, B., Fu, J., Qu, X., Li, L., Dai, M., Tan, C., Chen, H., & Wang, X. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02165-4 · Cited by 35

AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance

Zhang, H., Wang, Y.-J., Zhang, Y.-K., Wang, D.-S., Kathawala, R. J., Patel, A., Talele, T. T., Chen, Z.-S., & Fu, L.-W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.008 · Cited by 34

Different proteome pattern of epidermal growth factor receptor–positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment

Skvortsov, S., Sarg, B., Loeffler-Ragg, J., Skvortsova, I., Lindner, H., Werner Ott, H., Lukas, P., Illmensee, K., & Zwierzina, H. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1551.3.12 · Cited by 33

HER3 Alterations in Cancer and Potential Clinical Implications

Kilroy, M. K., Park, S., Feroz, W., Patel, H., Mishra, R., Alanazi, S., & Garrett, J. T. (2022) · Cancers · doi:10.3390/cancers14246174 · Cited by 21

A ligand-receptor interactome atlas of the zebrafish

(2023) · doi:10.1016/j.isci.2023.107309 · Cited by 18

Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways

Kamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., Poddubskaya, E., et al. (2023) · Cells · doi:10.3390/cells12162022 · Cited by 14

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

(2023) · doi:10.3390/ijms242115981 · Cited by 14

Metabolism and Pharmacokinetics of Allitinib in Cancer Patients: The Roles of Cytochrome P450s and Epoxide Hydrolase in its Biotransformation

Lin, L., Xie, C., Gao, Z., Chen, X., & Zhong, D. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056341 · Cited by 11

Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges

Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6